{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T10:43:31.850874+00:00","company":{"ticker":"INTI","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc."},"pagination":{"limit":100,"returned":1,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"b5a6acd9d4c1dde15b55a70a4bc9dfb90516b0f0","cik":1042418,"ticker":"INTI","company_name":"Inhibitor Therapeutics, Inc.","filed_at":"2026-02-24T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"an institutional investor","effective_date":"2026-02-19","item_codes_triggered":["1.01"],"value_text":"$3,000,000"},"claim":"Inhibitor Therapeutics, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $3,000,000 (effective 2026-02-19).","evidence_excerpt":"On February 19, 2026, Inhibitor Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ SPA ”) with an institutional investor (the “ Investor ”), for certain financing (the “Financing”), pursuant to which the Company has agreed to sell to the Investor 12,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”) and to issue to the Investor a Common Stock Purchase Warrant to purchase up to 7,000,000 shares of Common Stock (the “Warrant”), in consideration for the Investor’s investment of $3,000,000 therefor ($0.25 per share of Common Stock and accompanying Warrant).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-007821","anchor_url":"https://secwatch.observer/filing/0001493152-26-007821#claim-b5a6acd9d4c1dde15b55a70a4bc9dfb90516b0f0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315226007821/0001493152-26-007821-index.htm"}]}